INS and fatty liver disease: FGF1 is another secreted protein that has been shown to dampen hepatic glucose output by suppressing adipose lipolysis (Sancar et al., 2022), improve systemic insulin sensitivity by reducing adipose inflammation (Zhao et al., 2020), and alleviate hepatic steatosis, inflammation, and insulin resistance (Fan et al., 2019).